Comparison of the efficacy of combining left bundle branch pacing with either sacubitril/valsartan or enalapril in
Shengping Wang1, Yongsheng Feng2, Xiangyang Sun3
1Shengping Wang, Department of Cardiology, Dazhou Central Hospital,Dazhou, Sichuan Province, 635000, China.
Pakistan Journal of Medical Sciences
|February 15, 2024
Summary
Left bundle branch pacing combined with sacubitril/valsartan improved chronic heart failure (CHF) outcomes more than enalapril. This therapy enhanced cardiopulmonary function and reduced myocardial injury, improving patient quality of life.
Area of Science:
- Cardiology
- Medical Devices
- Pharmacology
Background:
- Chronic heart failure (CHF) remains a significant health concern.
- Left bundle branch pacing (LBBP) is an emerging therapy for CHF.
- Optimizing pharmacotherapy alongside LBBP is crucial for treatment efficacy.
Purpose of the Study:
- To compare the efficacy of LBBP combined with sacubitril/valsartan versus enalapril in treating CHF patients.
- To evaluate the impact on cardiac function, myocardial injury, and quality of life.
Main Methods:
- Retrospective analysis of 138 CHF patients from June 2020 to June 2022.
- Two groups: LBBP + sacubitril/valsartan (n=71) and LBBP + enalapril (n=67).
- Comparison of cardiac/cardiopulmonary indicators and MLHFQ scores pre- and post-treatment.
Main Results:
- The sacubitril/valsartan group showed significantly lower myocardial injury markers post-treatment (P<0.05).
- Higher cardiopulmonary function indicators were observed in the sacubitril/valsartan group.
- Patients receiving sacubitril/valsartan reported significantly lower MLHFQ scores.
Conclusions:
- LBBP combined with sacubitril/valsartan demonstrates superior therapeutic effects in CHF patients compared to LBBP with enalapril.
- This combination therapy effectively improves cardiopulmonary function and reduces myocardial injury.
- Sacubitril/valsartan offers a better quality of life improvement for CHF patients undergoing LBBP.
More Related Videos
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.6K
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.3K
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:22Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
513
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
513